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Clinically acquired resistance to MAPK inhibitor
(MAPKi) therapies for melanoma cannot be fully
explained by genomic mechanisms and may be
accompanied by co-evolution of intra-tumoral immu-
nity. We sought to discover non-genomic mecha-
nisms of acquired resistance and dynamic immune
compositions by a comparative, transcriptomic-
methylomic analysis of patient-matched melanoma
tumors biopsied before therapy and during dis-
ease progression. Transcriptomic alterations across
resistant tumors were highly recurrent, in contrast to
mutations, and were frequently correlated with dif-
ferential methylation of tumor cell-intrinsic CpG sites.
We identified in the tumor cell compartment supra-
physiologic c-MET up-expression, infra-physiologic
LEF1 down-expression and YAP1 signature enrich-
ment as drivers of acquired resistance. Importantly,
high intra-tumoral cytolytic T cell inflammation prior
to MAPKi therapy preceded CD8 T cell deficiency/
exhaustion and loss of antigen presentation in
half of disease-progressive melanomas, suggesting
cross-resistance to salvage anti-PD-1/PD-L1 immu-
notherapy. Thus, melanoma acquires MAPKi resis-
tance with highly dynamic and recurrent non-
genomic alterations and co-evolving intra-tumoral
immunity.INTRODUCTION
Understanding how melanomas acquire resistance to BRAF
inhibitors (BRAFi) via genetic alterations shown to reactivateCthe MAPK pathway (Nazarian et al., 2010; Shi et al., 2012a,
2012b, 2014a, 2014b; Van Allen et al., 2014; Wagle et al.,
2011) has guided the clinical development of BRAFi+MEKi
combinatorial therapy. Despite superior clinical benefits, the
double-drug approach commonly fails due to acquired resis-
tance (Larkin et al., 2014; Long et al., 2014b) caused by a similar
set of mutant genes responsible for acquired resistance to
BRAFi monotherapy (Long et al., 2014a; Moriceau et al., 2015;
Villanueva et al., 2013; Wagle et al., 2014). These shared muta-
tions, which include V600EBRAF amplification and single nucleo-
tide variants (SNVs) in NRAS, KRAS, MEK1/2, PTEN, CDKN2A,
and DUSP4, indicate that the reservoir of genomic diversity
strongly limits the long-term efficacy of dual (i.e., BRAFi+MEKi)
or likely higher-order (i.e., BRAFi+MEKi+ERKi) MAPKi therapy.
In addition to harboring heterogeneous genetic alterations in
the MAPK and PI3K-PTEN-AKT core pathways, melanomas at
distinct sites with acquired BRAFi resistance in any given patient
display extensively branched evolution (Shi et al., 2014a, 2014b).
Furthermore, many on-treatment tumors re-grow without any
clear genetic mechanism (Rizos et al., 2014; Shi et al., 2014b).
These observations suggested that a diverse array of melanoma
sub-clones, sometimes concurrent intra-tumorally, evolve to
circumvent the ‘‘bottleneck’’ of BRAFi therapy (Shi et al.,
2014b) and that exome-scale dissection of acquired MAPKi
resistance falls short of fully explaining clinical resistance. Earlier
(Johannessen et al., 2010; Nazarian et al., 2010) studies have
pointed to transcriptome-based mechanisms of acquired BRAFi
resistance. Given these leads, there is a clear need for compre-
hensive analyses of transcriptomic and epigenetic alterations
underlying acquired MAPKi resistance in patient-derived mela-
noma samples. Identification of highly recurrent, non-genomic
mechanisms may open the door to new combinatorial therapeu-
tic strategies.
In the current therapeutic landscape, salvage therapies for
patients with disease progression onMAPKi often involve immu-
notherapies, e.g., inhibitors of CTLA-4, PD-1 checkpoints, orell 162, 1271–1285, September 10, 2015 ª2015 Elsevier Inc. 1271
Figure 1. Landscape of Genomic, Transcriptomic, and Methylomic Alterations in Melanoma with Acquired MAPKi Resistance
(A) Matrix of disease progressive melanomas (n = 67; indicated by patient and then tumor numbers) on BRAFi or BRAFi+MEKi therapies and of genes whose
mutations cause acquired MAPKi resistance. Bottom, BRAF variant allelic frequencies or VAFs (resulting in V600E/K) adjusted by estimated tumor purities.
(B and C) Tiling of top 30 recurrent GOF (B) or LOF (C) gene-based events among cancer/melanoma/immune genes across 48 disease-progressive V600BRAF
mutant melanoma samples relative to patient-matched baseline melanomas (left, BRAFi; right, BRAFi+MEKi). GOF or LOF events defined as GOF:LOF ratioR2
(legend continued on next page)
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CSF-1R on tumor-associated macrophages. But it is not known
whether MAPKi-resistant melanomas are distinct in their im-
muno-phenotypes and susceptibilities to anti-CTLA-4 or -PD-1
therapies. In fact, studies are emerging which support immune
microenvironment modulation by BRAFi as a contributor to
in vivo anti-tumor effects. Thus, immune evasion may contribute
to acquired MAPKi resistance (Ferrari de Andrade et al., 2014;
Knight et al., 2013).
Hence, we sought a landscape perspective on the relative
contributions of genomic and non-genomic mechanisms to ac-
quired MAPKi resistance and co-evolutionary dynamics of the
intra-tumoral immune microenvironment in patient-derived mel-
anoma tissues.
RESULTS
Genetic Mechanisms of Acquired MAPKi Resistance in
Melanoma
We analyzed whole-exome sequences (WESs) of serial tumor bi-
opsies (baseline and acquired resistant tumors) and normal tis-
sues from patients with advanced melanoma treated with
MAPK inhibitor (MAPKi) regiments, which included single-drug
(i.e., BRAFi) or double-drug (i.e., BRAFi+MEKi) therapies (Table
S1A). When multiple disease-progressive or acquired MAPKi-
resistant tumors were obtained from patients, they were
compared to the same patient-matched baseline tumors. To
assess the degree to which functionally validated genetic mech-
anisms account for clinically acquired MAPKi resistance, we
visualized the recurrence of these mutations specific to or highly
enriched in single-drug and double-drug disease-progressive
(DP and DD-DP, respectively) melanomas (n = 67) relative to
matched baseline tumors (Figure 1A). These functionally vali-
dated mutations (Moriceau et al., 2015; Shi et al., 2014b)
included gain-of-function (GOF) events in V600E/KBRAF, NRAS,
KRAS, MEK1 or MAP2K1, PIK3CA, AKT1, AKT3 and loss-of-
function (LOF) events in PIK3R2, DUSP4, CDKN2A, PTEN. The
most recurrent resistance mutations were detected almost
mutually exclusively in V600E/KBRAF (copy-number gains in 15
of 67 or 22%) or RAS (single-nucleotide variants with or without
copy-number gains in 17 of 67 or 25%). Less prevalent resis-
tance mutations occurred at %9% (in PTEN, DUSP4) or asor LOF:GOF ratioR2, respectively. SNV, expressed non-synonymous single-nu
differential mRNA expression significantly correlated with differential CpG cluste
only. Genes in red, expression levels correlated with survival in the TCGA Melan
(D) Resistance driver genes proposed in the literature and their genetic and n
assignment based on each gene’s reported mechanism.
(E) Kaplan-Meier 10-year survival curves for c-MET and CTLA4 expression grou
follow-up durations were within 10 years. p values, log-rank test.
(F) Numbers of mRNA expression-correlated CpG clusters in resistant melanoma
grouped by up- or down-expression and Gene Ontology term enrichments.
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(H)Methylation changes at profiled CpG sites (green bubbles, CpG sites nominate
expression fold changes (FC). Both percentages of methylation change andmRNA
M238.
(I) Methylation changes across all expression-correlated CpG sites (top heat sca
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See also Table S1, Figure S1, and Data S1.
Csingleton events. Mutations in MITF, MEK2, RAC1, and NF1
were not specifically associated with resistant tumors. Impor-
tantly, 26 of 67 or 39% of resistant melanomas were not ac-
counted for by any validated mutational mechanism.
Landscape of Transcriptomic Alterations in Acquired
MAPKi Resistance
We profiled the temporal transcriptomic alterations in 48 DP
or DD-DP compared with patient-matched baseline melanoma
tissues (Table S1A) and integrated analysis (Figure S1A) of tem-
poral transcriptomic with expressed exomic alterations to
assess the combined recurrences of GOF and LOF gene-based
events. We rank-ordered recurrences of resistance-specific al-
terations based on the number of resistant samples and (in cases
of ties) of patients. The gene list included 855 cancer-, mela-
noma-, and MAPKi-resistance-, and immunotherapy-related
genes (Table S1B). Importantly, among the top 30 GOF and
LOF genes, transcriptomic alterations were generally more
recurrent per gene and affected more genes than exomic alter-
ations (Figures 1B, 1C, and S1B; Tables S1C and S1D). Notably,
transcriptional up- or down-expression occurred recurrently
and, respectively, in bona fide, mutated GOF (i.e., BRAF,
NRAS,KRAS) and LOF (i.e.,CDKN2A,DUSP4) resistance genes,
with the transcriptomic events exceeding the mutational
events in some cases (i.e., CDKN2A, DUSP4). Interestingly,
V600E/KBRAF was subject to not only mutational alterations
(copy-number gain) (eight of 16) (Shi et al., 2012b) (Figures 1A
and 1B), transcriptional up-expression (three of 16), and alterna-
tive splicing (five of 16) (Figure 1B), but also, in the absence of
aforementioned mechanisms, mutant allele-selective expres-
sion (Figure S1B; Table S1E). In total, GOF events in BRAF
occurred in 16 of 48 or 33% of resistant tumors. Similarly,
NRAS and KRAS GOF events (26 of 48 or 54%) were a mixture
of mRNA up-expression (16 of 26), mutational activation (11 of
26), and mutant allele-specific gene amplification (two of 26)
(Moriceau et al., 2015). In contrast to BRAF where both genetic
and non-genetic alterations affected the mutant gene selec-
tively, up-expression of WT NRAS or KRAS was commonly de-
tected in acquired MAPKi-resistant melanoma tumors and was
capable of conferring MAPKi resistance to sensitive melanoma
lines (Lidsky et al., 2014; Shi et al., 2014b) (Figure S1C). Also,cleotide variants; INDELs, expressed small insertion-deletions. Darker colors,
r methylation. Splice variants based on RT-PCR detection reported for BRAF
oma data.
on-genetic alterations in acquired MAPKi-resistant samples. GOF and LOF
ps among TCGA patients with BRAF mutant melanoma (n = 118) and whose
tissues and/or cell lines. Annotated genes from the overlapping CpG clusters
ble, a CpG site with anti-correlated differential mRNA expression versus gDNA
rofiled CpG sites (red, hyper-methylation; blue, hypo-methylation) across all
ight) of each gene (red, up-expression; green, down-expression).
d by aggregate tumor and cell line analysis as expression correlated) andmRNA
FC for each cell line sub-population were expressed relative to vehicle-treated
le, Pearson correlation R values) nominated by aggregate tumor and cell line
sub-population (versus vehicle-treated parental M238).
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we observed statistically significant overlaps between genes
that were recurrently mutated and recurrently differentially ex-
pressed (maximal recurrence capped at n = 5 resistance tumors;
Table S1F). This association was particularly strong with recur-
rent copy-number alterations. Non-copy-number genetic alter-
ations tended to be differentially expressed, although the statis-
tical significance was weaker. Of interest, four genes were
recurrently mutated in a GOF manner (excluding copy-number
variances [CNVs]) in at least five resistant tumors. These genes
were recurrently up-expressed and included NRAS and KRAS.
Most highly recurrent GOF events (Figure 1B; Table S1C) were
purely transcriptomic and could involve either tumor cell-intrinsic
or stromal differential gene expression. c-MET and IL-8 (San-
chez-Laorden et al., 2014) were up-expressed, respectively, in
21 of 48 or 44%and 19 of 48 or 40%of resistant tumors. Further-
more, c-FOS and MEOX2 encode tumor cell-intrinsic transcrip-
tional factors implicated in MAPKi resistance (Johannessen
et al., 2013). Other purely transcriptomic, highly recurrent GOF
events involved the macrophage markers (CD163 and
CD163L1). Up-expression of other genes such as CCL8 (critical
for chemotaxis of monocytes, lymphocytes, and granulocytes),
CSF3R (critical for granulocyte function), andNFKBIA suggested
inflammatory tumor infiltration. Thus, highly recurrent and GOF
transcriptomic events may reflect evolution in both the tumor
cell and immune compartments of acquired MAPKi-resistant
melanoma tissues.
The majority of highly recurrent LOF gene-based events (Fig-
ure 1C; Table S1D) arose from transcriptomic down-expres-
sions. These involved a gene most commonly mutated in Parkin-
son’s disease (LRRK2); an immune response modulation gene
(CTLA4); antigen presentation genes (B2M, HLA-A, HLA-B,
and TAP1); Wnt signaling genes (LEF1, FZD6, WNT11, and
WNT10A); and RTK genes (AXL, EGFR, ALK, NTRK2, and
FGFR2). CTLA4 may be down-expressed in both the immune
and tumor cell compartments, since in three melanoma expres-
sion data sets CTLA4 expression, in contrast to PDCD1 (PD-1)
expression, was less correlated with the expression of T cell
genes CD3, CD4, or CD8 (Table S1G). Also, we have observed
CTLA4 down-expression in several acquired MAPKi-resistant
melanoma cell lines compared to their parental counterparts
(data not shown). In the tumor cell compartment, CTLA4 may
be a direct therapeutic target of ipilimumab (Laurent et al.,
2013). Moreover, the finding here of frequent AXL and EGFR
down-expression in acquired MAPKi-resistant melanoma con-
trasted with previous cell line-based observations (Girotti et al.,
2013; Mu¨ller et al., 2014). We therefore evaluated systematically
the in vivo relevance of resistance mechanisms previously pro-
posed based on functional studies in cell lines (Figure 1D).
Despite the clear importance of CRAF as a convergent signaling
node for various mechanisms of resistance (Moriceau et al.,
2015; Nazarian et al., 2010; Shi et al., 2012b), CRAF (RAF1) itself
was not subject to a single genetic or non-genetic alteration.
Beyond assessing recurrence as evidence of selection, we
systematically gauged the impact of gene expression levels
(top versus bottom quartiles) on TCGA melanoma patients’
10-year survival (significance cutoff, log-rank test p % 0.05).
Importantly, c-MET and CTLA4 were not only the most recur-
rently up- and down-expressed genes, respectively, among1274 Cell 162, 1271–1285, September 10, 2015 ª2015 Elsevier Inc.resistant melanomas (Figures 1B and 1C) but also genes whose
expression levels portended survival significance (Figure 1E;
Table S1H), even after adjusting for age, tumor ulceration, and
stage (c-MET: Cox HR = 2.67 for the top quartile group, p value =
0.002, 95% CI, 1.4–5.0; CTLA4: Cox HR = 2.0 for the bottom
quartile group, p value = 0.024, 95% CI, 1.1–3.8). In addition to
assessing the survival impacts of gene expression levels, we
validated our recurrent transcriptomic GOF and LOF events us-
ing a publishedmicroarray study of an independent set of tissues
(Long et al., 2014a; Rizos et al., 2014). Again, c-MET was recur-
rently up-expressed in 8 of 35 (23%) MAPKi-resistant tumors
from 7 of 26 (27%) patients (Table S1I); CTLA4 was down-ex-
pressed in 9 of 35 (26%) MAPKi-resistant tumors from 7 of 26
(27%) patients (Table S1J).
A Common Methylomic Basis of Transcriptomic
Alterations
An integrated transcriptome-methylome analysis (Figures 1B
and 1C) revealed a subset of recurrent differential mRNA expres-
sion events, including those affecting c-MET, LEF1, and DUSP4,
as highly correlated with differential genomic DNA (gDNA) CpG
methylation (Table S1K). Methylation levels at 6,295 of all
33,874 (18.6%) CpG clusters were significantly correlated with
differential mRNA expression (Figure 1F; Supplemental Experi-
mental Procedures). To estimate the scope of tumor cell-intrinsic
events, we calculated the numbers of expression-correlated
CpG clusters across MAPKi-resistant tumors (n = 43 pairs) and
cell lines (n = 5 pairs) and found that 4,486 of 6,295 (71.2%)
expression-correlated CpG clusters were found in both (Figures
1F; Figure S1D). We then performed Gene Ontology (GO) enrich-
ment analysis of genes annotated to overlapping expression-
correlated CpG clusters; these genes included c-MET, LEF1,
and DUSP4 (Figure 1G; Table S1K). Genes with methylation-
correlated up-expression were enriched for wound healing and
receptor-linked or intracellular signaling, whereas genes display-
ing methylation-correlated down-expression were enriched for
cell adhesion and neuron differentiation (Figure 1F). In c-MET,
three CpG clusters (C1–3) with differential methylation were
negatively correlated with differential mRNA expression (Fig-
ure 1G). The extent and significance of these correlations
compared favorably with those between mRNA levels of
c-MET and its positive transcriptional factors (TFs) (Figure S1E).
In nearly all (90%) pairwise comparisons of tumors and cell lines,
differential c-MET mRNA expression could be accounted for by
at least one differential CpG cluster methylation (DbR 10% and
FDR adjusted p % 0.05). In contrast, only 48% displayed
a concordant differential expression pattern of at least one
c-MET TF (Figure S1F). Similarly for LEF1, DUSP4, and
EPHA2, differential methylation at specific CpG clusters nega-
tively correlated with differential mRNA expression (Figures 1G,
S1G, and S1H; Table S1K).
To corroborate expression-methylation correlations, we
analyzed data from 335 TCGAmelanoma samples. The Pearson
correlation between the absolute methylation levels at C1 and
normalized mRNA expression of c-MET was 0.48 (p < 2.2
e-16), while the correlation with MITF was 0.42 (p = 2.2e-15).
We also compared the top and bottom quartiles of methylation
levels (b values) in the c-MET CpG clusters and their mRNA
expression levels. In particular, C1 CpG hypo-methylation asso-
ciated strongly (Wilcoxon rank sum test p < 2.2 e-16) with high
levels of c-MET mRNA expression (Figure S1I; C2 CpG cluster,
not covered). Similar analysis for LEF1 and DUSP4 also sup-
ported expression-methylation correlations at specific CpG
clusters (Figures S1J and S1K). Overall, among 7,769 individual
expression-correlated CpG sites from 6,295 CpG clusters (Fig-
ure 1F), 4,086 CpG sites (53%) showed concordant differential
mRNA expression and CpG site methylation (top versus bottom
quartiles) among the TCGA melanoma tumors. Furthermore, we
examined our tissue-derived data for phenotypes inferred from
expression patterns of methylation-regulated genes such as
c-MET, LEF1, and DUSP4 (Table S1L). Genes whose differential
expression positively correlated with that of c-MET were en-
riched in theGO term ‘‘pigmentation during development’’; those
negatively correlated for ‘‘cell adhesion’’ and ‘‘positive regulation
of cell proliferation,’’ which suggested a motile phenotype (Data
S1A and S1B). On the other hand, differential expression of LEF1
and DUSP4 correlated strongly with enrichment of a mutant
BRAF signature (LEF1, Pearson R = 0.62 p = 8.9e-6; DUSP4,
Pearson R = 0.60 p = 1.8e-5) (Data S1C and S1D), which associ-
ated LEF1 and DUSP4 down-expression with reduced MAPK
addiction. Taken together, MAPK inhibition in BRAFmutant mel-
anoma may lead to epigenetic transcriptomic alterations with
functional consequences.
We then assessed whether BRAF inhibition in melanoma cell
lines would lead to temporally incremental and correlated alter-
ations between methylation and mRNA levels in c-MET, LEF1,
DUSP4, and in general. Using two human V600EBRAFmelanoma
cell lines, we profiled the methylomes and transcriptomes of ve-
murafenib (BRAFi)-selected sub-populations over time, including
drug-tolerant persisters (DTPs) (days of treatment), drug-tolerant
proliferating persisters (DTPPs) (weeks), and single-drug resis-
tant (SDR) sub-lines (months to years) as described (Shi et al.,
2014a). We observed in time-dependent BRAFi-selected sub-
populations (relative to vehicle-treated cells) methylation de-
creases at c-MET’s nominatedCpGclusters alongwithmRNA in-
creases. In contrast, methylation at nominated CpG clusters in
LEF1 and DUSP4 increased, while their mRNA levels decreased
with BRAFi treatment duration (Figure 1H; Data S1E). We also
examined the temporal methylation changes at all CpG sites
within all genes displaying differential expression between
vehicle-treated cells versus their isogenic SDR sub-lines. Impor-
tantly, the magnitudes of methylation changes were time depen-
dent; the directions of methylation changes were concordant
with the sites’ correlation scores independently derived from
the aggregate analysis of the tissue and cell line pairs (Figure 1I;
Data S1F and S1G). Thus, BRAFi treatments of cell lines led to
progressive methylation-expression changes akin to observa-
tions across MAPKi-sensitive versus resistant tumors.
Highly Recurrent c-MET Up-Expression Mediates
MAPKi Resistance
Because acquired MAPKi-resistant melanomas displayed highly
recurrent c-MET up-expression (Figure 1B), we compared
the absolute c-MET expression levels in three resistant and one
sensitive melanoma sub-groups: (1) c-MET-up-expression
(c-MET UP), (2) no c-MET differential expression, (3) c-METCdown-expression, and (4) baseline (Figure 2A) and observed
that c-MET UP resistant-melanomas in particular displayed
supra-physiologic levels of c-MET transcripts compared to the
sensitive, drug-naive melanomas in both our and the validation
cohorts. Additionally, the overall c-MET expression levels across
the spectrum of sensitive- and resistant-melanomas correlated
with single-sample enrichments of c-MET signatures generated
from the TCGA Melanoma data set (Figure 2B; Table S2). Genes
up-expressed (log2 FC R 2, FDR adjusted Wilcoxon p value%
0.05) in the top quartile of c-MET expression (versus the bottom
quartile) defined the c-MET_UP signature, and genes up-ex-
pressed in the bottom quartile defined the c-MET_DOWN or
DNsignature. Importantly, c-MET up-expression inMAPKi-resis-
tant melanomas generally concurred with positive enrichment
of the c-MET_UP TCGA signatures (and down-expression with
negative enrichment) (Figure 2C). By combining the transcrip-
tomic analysis of RTK genes in both discovery and validation
data sets (n = 82 differential expressions), we found that another
RTK EPHA2, which like c-MET has been nominated as a cancer
metastasis gene, was up-expressed (n = 25) in a largely mutually
exclusive manner to c-MET up-expression (n = 29) (one-sided
Fisher’s exact test p value = 0.031; odds ratio 0.34) (Figure 2D).
EPHA2 up-expression among MAPKi-resistant melanomas also
occurred in a supra-physiologic range (Figure S2A), and its top-
quartile expression associated significantly with worse patient
survival (Figure S2B). Using available patient-matched FFPE
samples (Figure 2E), we detected relative c-MET protein up-
expression in disease progressive tissue sections (Figure 2F)
using a validated antibody (Figure S2C) and found c-MET up-
expression in MAPKi resistance to be tumor cell-intrinsic.
We then assessed the functional role of tumor cell-intrinsic,
supra-physiologic c-MET up-expression using two triplets of
isogenic cell lines where the drug-resistant sub-lines were (1)
derived from the M229 and SKMEL28 human V600EBRAF mela-
noma cell lines by chronic BRAFi (vemurafenib) (single-drug
resistance or SDR) or BRAFi (vemurafenib)+MEKi (selumetinib)
(double-drug resistance or DDR) treatment (Figure 3A) and (2)
shown to display dramatic mRNA and protein up-expression of
c-MET compared to their parental cell lines. In stark contrast
to acquired MAPKi-resistant cell lines driven by genetic mecha-
nisms such asNRASmutations, V600EBRAF amplification, and/or
MEK1mutations, acquired SDR or DDR sub-lines up-expressing
c-MET was highly refractory to downstream MAPK suppression
(Figure 3A). Despite this, stimulation of cells by HGF addition
during the course of BRAFi (for parental and SDR cell lines) or
BRAFi+MEKi (for DDR cell lines) treatment accelerated p-ERK
recovery or reactivation only in resistant cell lines and in a
manner reversible by co-treatment with an inhibitor of c-MET,
crizotinib (Figure 3B). c-MET up-expression was accompanied
by enhanced activation-associated phosphorylation (Y1234/
1235) and p-AKT (T308, S473) induction, which could be
augmented by HGF stimulation and repressed by crizotinib
treatment (Figure 3C). These studies indicate that supra-physio-
logic c-MET up-expression in SDR and DDR sub-lines mediates
MAPK-redundant survival signaling.
Importantly, HGF stimulation enhanced the clonogenic sur-
vival of M229 and SKMEL28 SDR and DDR sub-lines cultured
with MAPK inhibitor(s) but not the parental cell lines (withoutell 162, 1271–1285, September 10, 2015 ª2015 Elsevier Inc. 1275
Figure 2. Recurrent c-MET Up-Expression in Disease Progressive Melanomas
(A) c-MET mRNA expression levels in distinct subsets of disease progressive sample. p values, Wilcoxon rank-sum test.
(B) Pearson correlation (p values, t test) of the c-MET mRNA expression levels in all baseline and disease progressive melanoma samples (discovery, n = 59;
validation, n = 61) with enrichment scores of the TCGA melanoma-derived c-MET signatures.
(C and D) Tiling of c-MET signature enrichment (orange and blue, positive and negative enrichments) (C) and differential c-MET (C and D) and EPHA2 (D)
expression (red and green, up- and down-expression) across disease progressive melanomas (DD-DP samples, gray) (both discovery and validation cohorts, D).
(E and F) Levels of c-METmRNA (E) and protein (F) (for samples in red) in patient-matched pairs where resistance-associated c-METmRNA up-expression was
detected (ruler, 50 mm).
See also Table S2 and Figure S2.
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Figure 3. c-MET Up-Expression Drives Acquired MAPKi Resistance
(A) Three-day MTT survival assays of two isogenic melanoma triplets in response to single MAPKi (BRAFi), double MAPKi (as indicated), or triple MAPKi
(BRAFi+MEKi+ERKi). BRAFi, vemurafenib; MEKi, selumetinib; ERKi, SCH772984 (all in mM). Error bars, SEM, n = 5; normalized to DMSO vehicle as 100%.
(B)Western blot (WB) analysis of p-ERK recovery in both isogenic triplet cell lines in response to a single dose of 1 mMBRAFi (P, SDR) or BRAFi+MEKi (DDR) under
four conditions (DMSO/PBS, crizotinib (0.1 mM)/PBS, DMSO/HGF (20 ng/ml), and HGF/crizotinib). SDR and DDR sub-lines were first plated without MAPKi for
16 hr. Loading controls, ERK.
(C) WB levels of activation-associated phosphorylation and total levels of indicated proteins in response to vehicle, crizotinib, and/or HGF treatments (1 hr).
TUBULIN, loading control. Only SDR and DDR lines were cultured with MAPKi.
(D) Long-term (10 days) clonogenic assay (P, no inhibitor; SDR, 1 mM BRAFi; DDR, 1 mM BRAFi+MEKi) ± HGF and crizotinib (mM). Growth quantifications are
relative to cultures without HGF and crizotinib (in red).
(E) WB analysis of c-MET knockdown (short and long exposures).
(F) Long-term (10 days) clonogenic assay ± c-MET knockdown. Growth quantifications relative to shScramble (shSCR) controls.MAPKi) (Figure 3D), indicating that the growth-promoting effect
of HGF depended on c-MET up-expression. Also, treatments
with low concentrations of crizotinib reduced the clonogenic
growth of SDR and DDR sub-lines, with or without HGF stimula-
tion, but not the parental melanoma cell lines. Furthermore,Cc-MET knockdown using two independent small hairpin RNA
(shRNAs) (Figure 3E) preferentially reduced the clonogenic
growth of resistant melanoma sub-lines (Figure 3F). Collectively,
these data argue that melanoma cells can acquire MAPKi resis-
tance via addiction to c-MET up-expression and hyper-activity.ell 162, 1271–1285, September 10, 2015 ª2015 Elsevier Inc. 1277
Figure 4. b-Catenin-LEF1 Up- and YAP1 Downregulation Sensitize Resistant Melanoma to MAPKi
(A) Tiling of LEF1_UP gene signature enrichment and differential expression of LEF1, FZD6, and CCND1 across disease progressive melanomas.
(B) Indicated mRNA expression levels in LEF1 down-expressed, MAPKi-resistant melanomas versus baseline melanomas. p values, Wilcoxon rank-sum test.
(C) Three-day survival assays of resistant melanoma cell lines at varying [BRAFi] and [BRAFi+MEKi], ± GSK3bi (10 mM CHIR99021) or LEF1 overexpression.
(D) Clonogenic assays of resistant cell lines (cultured with 1 mM MAPKi) ± LEF1 overexpression, with DMSO (9 days) or GSK3bi (10 mM, 18 days).
(E) As in (A) except signature enrichment and differential expression indicated for YAP1.
(F) Western blot analysis of indicated parental (P) and isogenic resistant cell lines for levels of total and phospho-YAP1 andmarker proteins in cytoplasmic (C) and
nuclear (N) fractions (T, total lysate). MAPKi, 1 mM.
(G) Three-day survival assays of resistant melanoma cell lines at two indicated [BRAFi] or [BRAFi+MEKi], ± YAP1 knockdown.
*p < 0.01, **p < 0.001, ***p < 0.0001, Student’s t test p values, ± LEF1 overexpression (C) or shVector versus shYAP1 (G) Error bars, SEM; n = 5 per group.
See also Figure S3 and Table S3.Altered b-Catenin-LEF1 and YAP1 Signaling Reduces
Apoptosis and Promotes MAPKi Resistance
Whereas supra-physiologic c-MET up-expression in resistant tu-
mors correlated strongly with its down-methylation, LEF1 down-
expression correlated with its up-methylation (Figures 1C and
1G) and resulted in infra-physiologic expression levels (Figures
4A, 4B, and S3A). Moreover, LEF1 (and its related pathway
genes, FZD6 and CCND1) down-expression concurred strongly
with negative enrichment of TCGA melanoma LEF1_UP signa-
tures (Figure 4A; Table S3), indicating downregulation of b-cate-
nin-LEF1 transcriptional activity. Consistently, we detected
robust LEF1 protein down-expression in resistant tumors using
a FFPE-validated antibody (Figures S3B and S3C). We also de-
tected LEF1 down-expression in a panel of SDR or DDR cell lines
(versus parental cell lines) (Figure S3D). To understand whether1278 Cell 162, 1271–1285, September 10, 2015 ª2015 Elsevier Inc.b-catenin-LEF1 signal downregulation promoted MAPKi resis-
tance, we tested whether restoration of LEF1 expression and/
or b-catenin-LEF1 signaling in these MAPKi-resistant melanoma
cell lines would re-sensitize them toMAPKi. GSK3b inhibition us-
ing CHIR99021 strongly decreased p-b-catenin (Ser33/37 and
Thr41) and increased total b-catenin levels in the parental cell
lines (e.g., Figure S3E); these effects of GSK3b inhibition were
weaker in the SDR and DDR cell lines (Figure S3F), consistent
with a compromised b-catenin-LEF1 pathway. Importantly,
GSK3bi strongly re-sensitized SDR andDDRmelanoma cell lines
to BRAFi and BRAFi+MEKi, respectively, and this re-sensitiza-
tion to MAPKi was augmented by LEF1 re-expression in short-
term (Figure 4C) and long-term (Figure 4D) survival assays.
Hence, recurrent b-catenin-LEF1 downregulation promotes
MAPKi insensitivity.
Although analysis of recurrent, differential mRNA expression
can uncover key transcriptome- and methylome-based resis-
tance genes such as c-MET and LEF1, we asked whether
gene signature-based analysis would identify resistance genes
with post-transcriptional mechanism. One such candidate resis-
tance gene, YAP1, was supported by recurrent signature enrich-
ment without necessarily its mRNA up-expression in both
MAPKi-resistant tumors and cell lines (Figure 4E). Importantly,
western blot analysis showed that these acquired MAPKi-resis-
tant cell lines harbored increased total levels of YAP1 and phos-
pho-YAP1, in the cytoplasmic, nuclear or both compartments,
compared with levels in the untreated parental cell lines (Fig-
ure 4F). In fact, BRAFi treatment of the M229 parental line led
to an accumulation of YAP1 protein but not its mRNA level.
Consistently, we showed, using a validated anti-YAP1 antibody
(Figure S3G), that YAP1 protein was up-expressed in disease
progressive melanoma tissues (despite the lack of YAP1
mRNA up-expression) compared to their baseline tissues (Fig-
ure S3H). Notably, in SDR and DDR melanoma cell lines with
positive enrichment of YAP1 signatures, YAP1 knockdown
(Figure S3I) re-sensitized these resistant cell lines to BRAFi or
BRAFi+MEKi (Figure 4G).
Given known intersections between the b-catenin-LEF1
and YAP1 signaling pathways in other biological contexts, we
explored whether b-catenin-LEF1 downregulation and YAP1 up-
regulation may co-regulate resistance. Inhibition of GSK3b with
overexpression of LEF1 in YAP1 signature-enriched, MAPKi-
resistant cell lines strongly induced apoptosis, as measured by
PARP1 cleavage (cPARP1) (Figure 5A), suggesting that b-cate-
nin-LEF1 signaling promoted apoptotic sensitivity to MAPKi.
Since BIM levels are known to modulate melanoma sensitivity
to apoptotic induction, we tested whether GSK3bi treatment
and restoration of LEF1 expression would promote the levels
of the pro-apoptotic protein BIM. Indeed, this combination
accelerated and/or augmented BIM accumulation in all acquired
MAPKi-resistant cell lines tested (Figure 5B). Interestingly,
while GSK3b inhibition and YAP1 knockdown each induced
apoptosis, they together induced greater apoptosis (Figure 5C)
in association with BIM accumulation (Figure 5D). Consistently,
GSK3b inhibition with YAP1 knockdown resulted in the most
extensive clonogenic growth suppression of acquired MAPKi-
resistant melanoma cell lines (Figure 5E). Conversely, heterolo-
gous overexpression of YAP1, beyond the endogenously up-
expressed levels in these resistant cell lines, reduced apoptosis
and BIM induction by GSK3b inhibition (Figures 5F and 5G).
Accordingly, exogenous YAP1 overexpression strongly rescued
MAPKi-resistant melanoma cells from clonogenic growth sup-
pression elicited by GSK3b inhibition (Figure 5H). Together,
these results support the concept that b-catenin-LEF1 and
YAP1 signaling antagonistically co-regulate the tumor cell-
intrinsic, apoptotic threshold of melanoma to MAPKi.
Acquiring MAPKi Resistance Can Deplete and Exhaust
Intra-tumoral CD8 T Cells
Among the most recurrent gene-based transcriptomic alter-
ations in acquired MAPKi resistant melanomas were those
related to tumor-associated immune cells or inflammatory states
(Figures 1B and 1C). By quantifying changes in gene set enrich-Cment values between resistant versus matched baseline tumors,
we found that the most highly recurrent net positive enrichments
were in signatures related to NF-kB signaling or inflammation
(from C6 oncogenic signatures, Broad Institute), monocyte func-
tions (C7 immune signatures), and additional immune and
inflammation signatures related to, for instance, T cell function,
serum response, and NF-kB signaling (C2 chemical and genetic
perturbation signatures) (Data S2A–S2C). In assessing a poten-
tial relationship between monocyte function and intra-tumoral
inflammation, we found that the enrichments (positive or
negative) of NF-kB/inflammation and of monocyte activation
signatures aligned correspondingly with each other (Figure 6A).
Additionally, positive enrichment of NF-kB or inflammation
signatures related strongly to the up-expression of a panel
of M2 macrophage markers, including those among the top
GOF genes such as CD163 and CD163L1 (Figure 1B). Thus,
changes in tumor-associated macrophages likely contributed
to distinct inflammatory states in melanomas with acquired
MAPKi resistance.
Given that tumor-associated M2 macrophages can antago-
nize the recruitment and effector functions of T cells, we
analyzed the relationship between macrophage-associated
inflammation with expression markers of T cell abundance/func-
tion. Interestingly, we found that a subset (group B, Figure 6A)
among MAPKi-resistant melanomas with enhanced expression
of macrophage-associated inflammation (groups A+B, Fig-
ure 6A) was strongly associated with reduced expression of
T cell marker/function. CSF1R and CD163 (M2 macrophage
markers) expression levels displayed a highly positive correlation
that was comparable to the correlation between CD8A and
CD8B expression levels (Data S2D and S2E), indicating that
the majority of CSF1R up-expression occurred in CD163-posi-
tive macrophage cells. Furthermore, negative enrichment of
the NF-kB signature in resistant tumors was significantly associ-
ated with expression loss of tumor-associated M2 macrophage
markers,CD163 orCSF1R (Figure 6B). The putative deficiency of
tumor-associated M2 macrophages and a pausi-inflammatory
tumor microenvironment marked a second subset of intra-
tumoral T cell loss. Importantly, a similar pattern of immune re-
composition was observed in the validation data set (Data
S2F). Thus, the states of macrophage and T cell inflammation
co-evolved with MAPKi resistance, suggesting the potential util-
ity of CSF1R inhibitors.
We investigated further the dynamic loss of CD8 T cells in a
significant subset of acquired MAPKi resistance. We observed:
(1) a concurrent down-expression of CD8A, CD8B, PDCD1
(PD-1), and TNFRSF9 (4-1BB/CD137), where PDCD1 (PD-1)
and TNFRSF9 (4-1BB/CD137) expression marks the melanoma
tumor-reactive CD8 T cell population (Gros et al., 2014) (Table
S4), and (2) a suppression of CD8 T cell numbers (reflected by
the absolute CD8A expression values) to a level significantly
below the baseline range, and (3) lower CD8A (italicized) expres-
sion values in association with down-enrichment of the NF-kB
signature (Figure 6C; Data S2G). We could directly visualize sup-
pression of CD8 T cell numbers using anti-CD8 (along with differ-
ential levels of macrophages using anti-CD163) immunofluores-
cence of fixed tissues from tumor sections adjacent to those
subjected to RNA sequencing (RNA-seq) (Figure 6D). Givenell 162, 1271–1285, September 10, 2015 ª2015 Elsevier Inc. 1279
Figure 5. b-Catenin-LEF1 and YAP1 Co-regulate Apoptotic Sensitivity of Acquired MAPKi-Resistant Melanoma Cells
(A) Western blot (WB) analysis of indicated resistant melanoma cell lines (cultured with 1 mM MAPKi) for levels of cleaved PARP1 (cPARP1), LEF1, and GAPDH
(loading control). Cells were treated with DMSO or GSK3bi (10 mM CHIR99021), ± LEF1 overexpression, for 1–2 days.
(B–D) As in (A), except cell lysates were collected at 12 and 24 hr and probed for BIM levels (B and D) or harbored shVector (V) or shYAP1 (C and D).
(E) Clonogenic assays of indicated resistant cell lines (cultured with 1 mM MAPKi) treated with DMSO or GSK3bi (10 mM CHIR99021) for 14 days, ± YAP1
knockdown.
(F and G) As in (A), except cells ± YAP1 overexpression and WBs were probed for YAP1 and cPARP1 (F) or BIM (G).
(H) As in (E), except ± YAP1 overexpression; all cultures for 14 days except M238 DDR cultures with GSK3bi (22 days).highly recurrent down-expression of antigen presentation genes
(e.g., B2M, HLA-A, HLA-B, and TAP1) (Figure 1C), we analyzed
the potential relationship in the dynamic expression of genes
related to antigen presentation, dendritic cells, and CD8 T cells
(Figure 6E). This revealed a consistent concurrence between
levels of intra-tumoral antigen presentation and CD8 T cells/
function in both the discovery and validation tissue cohorts, indi-
cating that 50% of all resistant melanoma displayed a relative
loss of CD8 T cells and their function (Data S2H). This was not
surprising considering a general and tight correlation between
CD8A versus TAP1 or B2M expression levels among all mela-1280 Cell 162, 1271–1285, September 10, 2015 ª2015 Elsevier Inc.nomas in our cohort (Figures 6F and 6G), in the validation cohort
(Figure S4A), and in the TCGA melanoma cohort (Figure S4B).
Importantly, the subgroups of resistant melanomas with CD8A
down-expression or of all melanomas with the lowest quartile
of CD8A expression displayed a high ratio of EOMES/CD8A
expression (where EOMES is a transcription factor related to
T cell exhaustion (Twyman-Saint Victor et al., 2015) (Figures
6H and S4C). Reduced intra-tumoral CD8A expression was
associated with increased ratios of expression in a panel of
CD8 T cell exhaustion genes to CD8A (Figure 6I), and the sub-
group of resistant tumors with CD8A down-expression was
strongly associated with T cell exhaustion (Figure S4D). More-
over, expression levels of the CD8 T cell marker (CD8A), its func-
tional feedback (PDCD1/PD-1, CD274/PD-L1) driven by IFN-g,
and its effector function (geometric average of PRF1, GZMA ex-
pressions defined as a cytolytic score (Rooney et al., 2015) were
found to be clinically important, as they impacted patient survival
in the TCGA melanoma data (Figure 6J). Lastly, the dynamic na-
ture of intra-tumoral CD8 T cells before and during progression
on MAPKi therapy was further underscored by an inverse rela-
tionship in the expression levels of these CD8 T cell marker/func-
tion genes at baseline and during disease progression (Figures
6K and S4E). In short, MAPKi resistance and CD8 T cell defi-
ciency/exhaustion co-evolve frequently with downregulation of
the antigen presentation machinery.
DISCUSSION
Unraveling the complexities of cancer genomics has relied
heavily on the recurrence of genetic events as a sine qua non ev-
idence for functional selection. However, when the evolution of
melanoma treated with MAPK inhibitor(s) was actually sampled
by serial biopsies, the genetic variants positively selected by
the inhibitors were not highly recurrent and together could not
explain clinical relapse comprehensively. Here, we showed
that gene-and signature-based transcriptomic alterations in ac-
quired MAPKi-resistant melanoma were highly recurrent. Tran-
scriptomic alterations, unlike mutations, could not be attributed
to tumor or stromal/immune cells without specific validations
through histologic analysis of tissues and functional analysis of
cell line models of acquired resistance. We highlighted specific
genes (c-MET, LEF1, YAP1) and pathways subject to recurrent
differential regulation in resistant tumor cells. That c-MET up-
and LEF1 down-expression cause acquired MAPKi resistance
is reminiscent of findings that HGF stimulation and b-catenin
activation can modulate innate BRAFi sensitivity (Biechele
et al., 2012; Straussman et al., 2012). Thus, determinants of
innate versus acquiredMAPKi resistancemay converge on path-
ways. This is further exemplified in studies showing PI3K-AKT
activation in both early and late resistance (Obenauf et al.,
2015; Shi et al., 2011, 2014a, 2014b). As YAP1 signal activation
in resistant melanoma appeared post-transcriptional, its altered
post-translational regulation requires additional studies. Overall,
genetic and epigeneticmechanisms can account broadly for dis-
ease progression onMAPKi therapies and contribute extensively
to intra-tumor/patient and inter-patient tumor heterogeneity (Fig-
ures 7A and 7B).
For some of the gene targets of transcriptomic and functional
alterations identified in MAPKi resistance (e.g., c-MET, TAP1,
B2M), their baseline expression ranges in the TCGA data were
shown to impact patient survival. This point is of particular impor-
tance given the highly dynamic (i.e., out of range) up-expression
(c-MET, YAP1, EPHA2; Paraiso et al., 2015) or down-expression
(LEF1, TAP1, B2M, CD8A, DUSP4) events occurring with the
evolution of MAPKi-resistant in melanoma (Figure 7C). It may
not be surprising to find that the expression levels of genes
reflective of CD8 T cell and antigen presentation abundance
and function were linked to patient survival given the relatively
high mutation/neoantigen load and immunogenicity of mela-Cnoma and the clinical efficacy of PD-1 targeting in melanoma.
We also presented evidence that differential CpG methylation
likely underlay dynamic expression of the tumor cell-intrinsic
transcriptome during the evolution of MAPKi resistance.
Broadly, the selection of distinct transcriptomic-methylomic
state(s) imposed by MAPK-targeting likely impacts the panoply
of melanoma phenotypes or ‘‘hallmarks’’ (Figure 7D).
Transcriptomic analysis of temporally paired tumor biopsies
revealed highly recurrent evolutionary events in the immune
compartment. That half of all melanoma with acquired MAPKi
resistance displayed a profound CD8 T cell deficiency and
exhaustion should bear on the selection of patients for salvage
immunotherapies, specifically PD-1 inhibitors, and the clinical
sequencing of immune checkpoint versus MAPK inhibitors.
We showed that the expression levels of PD-1, T cell effector
genes, and a marker of melanoma tumor-reactive CD8 T cells,
TNFRSF9 (4-1BB/CD137), tightly correlated with CD8A expres-
sion. Specifically, CD8A expression in disease progressive tu-
mors can decrease with respect to not only the patient-matched
baseline expression level but also the general baseline expres-
sion range (i.e., infra-physiologic). This distinctive expression
pattern of CD8A, in both relative and absolute terms, denotes
both CD8 T cell depletion and exhaustion. Finally, since high
intra-tumoral CD8 T cell inflammation before therapy was corre-
lated with a loss of intra-tumoral CD8 T cell inflammation at
disease progression, studies are warranted to examine the
functional contributions of immune evasion to acquired MAPKi
resistance, as CD8 T cells may contribute to the anti-tumor
response of BRAF inhibition in vivo (Knight et al., 2013; Mok
et al., 2015).
To anticipate cancer evolution, the iterative process of under-
standing acquired resistance and informing next-generation
therapies should incorporate analysis of both genomic and
non-genomic selection, including tumor and host-immune co-
evolution. The extent of non-genomic and immune evolution in
acquired MAPKi resistance documented here mandates a
comprehensive analysis of early tumor responses to therapies
in order to understand the true influence of targeted therapies
on cancer evolution.EXPERIMENTAL PROCEDURES
Analyses of Tumor Specimens
Patient-matched normal tissues and melanoma tumors (pre-treatment, during
disease progression) were obtained with the approval of institutional review
boards (IRBs) and patients’ consents. Ninety specimens were subjected to
exome, transcriptome, and methylome profiling. WES and mRNA expression
profiles were performed using pair-end sequencing with read length of 2 3
100 bps (Illumina HiSeq2000), except that microarray was used for tumors
from patients 10–14, whereas data for patients 11–14 were taken from a pub-
lished study (Long et al., 2014a; Rizos et al., 2014). Paired methylome profiles
were generated from the Illumina Infinium Methyl450K array.
Bioinformatic Analysis
We re-analyzed WES data from previous studies (Moriceau et al., 2015; Shi
et al., 2014b) and defined differential gene expression (DGE) events based
on the RNA-seq (2-fold cutoff) as concordant DGE calls from at least two of
three programs (Supplemental Experimental Procedures). Analysis of the mi-
croarray data (DGE cutoff at 1.5-fold) of patient 10 was performed using the
Oligo R package and of the validation data set using the beadarray R package.ell 162, 1271–1285, September 10, 2015 ª2015 Elsevier Inc. 1281
Figure 6. A Pro-tumorigenic Immune Microenvironment Co-evolves with MAPKi Resistance
(A) Tiling of differential gene signature enrichment (orange, positive; blue, negative) and expression (red, up; green, down) across disease progressivemelanomas
(DD-DP samples shaded gray).
(legend continued on next page)
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Figure 7. Melanoma Evolution Driven by
MAPK-Targeted Therapies
(A) Recurrence of alterations and heterogeneity of
mechanisms across proposed resistance genes
and across acquired resistant tumors grouped by
patients.
(B) Scope of genomic and/or non-genomic ac-
quired resistance mechanisms.
(C) Dynamic gene expression alterations during the
evolution of acquired resistance. Black circle and
triangle, distinct tumor subsets.
(D) Contributions of non-genomic alterations to
cancer phenotypes of acquire MAPKi-resistant
melanoma.For DGE of immune genes, we relaxed the cutoffs to 1.5-fold (RNA-seq) and
1.25-fold (microarray), as the immune compartments were smaller than the tu-
mor cell compartments. In addition to DGE, for each baseline and DP or DD-
DP sample, we tabulated the normalized gene expression levels, which were(B and C) Boxplots of mRNA levels detected in baseline versus subsets of MAPK-resistant melan
SCHOEN_NFKB_SIGNALING signature (B and C) or differential CD8A expression status (C).
(D) Anti-CD8 and -CD163 immunofluorescence of formalin-fixed, patient-matched melanoma tissues (ruler,
(E) Refer to (A).
(F and G) Correlations between mRNA levels of TAP1 (E) or B2M (F) versus CD8A.
(H) Boxplots of the ratio of EOMES/CD8AmRNA levels in baseline versus distinct subsets of MAPKi-resistant
(left) and in each quartile of CD8A expression across all tumor samples (right).
(I) Heatmaps (left, discovery; right, validation) showing expression ratios of T cell exhaustion genes to CD8A
(J) Ten-year survival of TCGA melanoma patients in the top and bottom quartile expression groups of indic
(K) Pearson correlations between mRNA levels at baseline versus the FC from baseline to MAPKi-resistant
p values by t test for Pearson correlations and by one-sided Wilcoxon rank-sum test for boxplots. FC cutoff a
Cell 162, 1271–1285, Sepexpressed in FPKM. Expressed SNVs or INDELs
were defined by FPKM values R0.1. CNV-related
DGE events were defined as concurrent copy-
number gain and RNA up-expression (log2 FC R
1 with q value %0.05) or copy-number loss and
RNA down-expression (log2 FC % 1, q value %
0.05). To analyze gene set enrichment of paired
samples, we estimated the enrichment of a gene
set based on the rank sum of fold changes of
genes in the set compared to all fold changes in
the sample (Wilcoxon rank-sum test; p value cut-
off %0.05; median of up- or down-expression
across all genes in the gene set R10%). For sin-
gle-sample gene set enrichments, values were
derived using the GSVA program. GO enrichments
were computed using DAVID.
For each CpG site in the array, the methylation
change was measured by the percentage methyl-
ation difference (Db) between baseline and resis-
tant samples. The p values for the change were
corrected for multiple hypotheses testing with
false discovery rates (FDR) q values %0.05
defining differential methylation. CpG clusters
were defined as a set of consecutive CpG sites
whose methylation changes correlated with their
nearest target gene’s mRNA expression changes
across all resistant samples and cell lines. Those
CpG sites with Pearson R correlation coefficient
(adjusted) p value %0.1 were defined as expres-
sion-correlated, and their Pearson R coefficients
were defined as correlation scores. For each sam-
ple, we identified all CpG clusters with significant
differential methylation (q value % 0.05, jDbj R
10%) and significant DGE (q value % 0.05, jlog2j FCj R 1) and assessed
whether the direction of the changes of methylation and mRNA expression
was consistent with the overall correlation between the CpG cluster and
gene expression across all samples. Based on this, we nominated DGE eventsomas categorized by enrichment status of the
50 mm; white text, values of mRNA fold change).
melanoma based on CD8A fold change (FC) status
. Bottom, absolute mRNA levels of CD8A.
ated genes (p values, log-rank test).
melanomas.
tR1.5. See also Figure S4, Table S4, and Data S2.
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as driven by differential methylation at the expression-correlated CpG
cluster(s).
Cell Culture, Inhibitors, and Constructs
Cell lines were maintained in DMEM with 10% heat-inactivated FBS, 2 mmol/l
glutamine in a humidified 5% CO2 incubator. Stocks and dilutions of crizotinib
(Selleck Chemicals), PLX4032 (Plexxikon), AZD6244 (Selleck Chemicals), and
CHIR99021 (Tocris Bioscience) were made in DMSO. HGF (Life Technologies)
was suspended in PBS. MTT and clonogenic assays were performed and
quantified as described (Moriceau et al., 2015). shc-METs were cloned using
the pLL3.7-GFP vector (sequences available upon request); shYAP1s were
purchased from Dharmacon (vector pLK0.1); and LEF1, YAP1, and NRAS
WT or Q61R were constructed in pRRLsin-cPPT-CMV-IRES-GFP and pLVX-
Tight-puro lentiviral vectors.
Protein Detection
Cell lysates for western blots were made in RIPA buffer (Sigma) supplemented
with protease (Roche) and phosphatase (Santa Cruz Biotechnology) inhibitor
cocktails. We used the NE-PER Nuclear and Cytoplasmic extraction reagents
(Pierce Biotechnology) for cellular fractionation. For immunohistochemistry
(IHC), after deparaffinization and rehydration, tissue sections were antigen-
retrieved at 95C for 30 min. Immunostaining with anti-c-MET (Cell Signaling
Technology) was performed using a streptavidin–biotin, horseradish peroxi-
dase and DAB chromogen (Vector Laboratories). IHC with anti-YAP1 (Santa
Cruz Biotechnology) and anti-LEF1 (Santa Cruz Biotechnology) was per-
formed using alkaline phosphatase, vulcan fast red chromogen (Biocare
Medical), and hematoxylin counterstain (Thermo Scientific). Immunostaining
with anti-CD8 (Dako) and anti-CD163 (Abcam) was visualized by TRITC- and
FITC-labeled secondary antibodies, respectively, and nuclei were counter-
stained by DAPI.
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